[Nanoparticles for cancer therapy]

Area of Science:

• Oncology
• Nanomedicine
• Drug Delivery

Background:

• Nanoparticles offer significant potential in oncology for diagnosis, therapy, and theragnostics.
• A notable gap exists between experimental nanoparticle research and clinical applications in cancer treatment.
• Current clinical use of nanoparticles is limited, with some drug-releasing formulations approved for specific cancer types.

Purpose of the Study:

• To review the current status and clinical translation of nanoparticles in cancer therapy.
• To highlight the challenges and successes in developing nanoparticles for oncological applications.
• To discuss the future prospects of advanced nanoparticle formulations in cancer care.

Main Methods:

• Review of existing clinical studies and approved nanoparticle-based cancer therapies.
• Analysis of nanoparticle formulations, including liposomes and albumin-bound nanoparticles.
• Examination of specific applications such as gene-directed enzyme prodrug therapy (GDEPT) and trans-arterial chemo-embolization (TACE).

Main Results:

• Limited clinical translation of cell-containing nanoparticles, with one notable exception using gene-directed enzyme prodrug therapy (GDEPT).
• Several cell-free, drug-releasing nanoparticles are in clinical use, particularly for liver tumors (e.g., doxorubicin for TACE).
• Liposomal formulations of paclitaxel and irinotecan have been utilized in pancreatic cancer, with nanoparticle-albumin-bound paclitaxel (NAB-paclitaxel) approved for first-line pancreatic cancer therapy.

Conclusions:

• Nanoparticle-albumin-bound paclitaxel and liposomal irinotecan represent significant clinical advancements for pancreatic cancer.
• Despite promising experimental data, the clinical adoption of novel nanoparticle formulations for cancer therapy remains slow.
• Further research and clinical trials are essential to realize the full potential of advanced nanoparticles in oncology.